Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal

Key Takeaways Gilead will acquire Ouro Medicines for $1.675B upfront plus $500M in milestones, boosting its pipeline.GILD gains OM336, a bispecific T-cell engager showing early promise in autoimmune diseases like AIHA and ITP.GILD is exploring a partnership with Galapagos to co-develop OM336 and share development costs and royalties.Gilead Sciences (GILD) has agreed to acquire privately held biotechnology company Ouro Medicines, strengthening its push into innovative therapies for autoimmune diseases.The de ...